Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12847277 | 1.00 | RIPK1 (0.68) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL5609128 | 0.94 | RIPK1 (0.60) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL5185803 | 0.81 | RIPK1 (0.64) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL3081755 | 0.81 | RIPK1 (0.64) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL22624001 | 0.81 | RIPK1 (1.00) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL22623858 | 0.81 | RIPK1 (1.00) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL5865833 | 0.80 | LMNA (0.52) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL11137800 | 0.79 | HRH1 (0.52) | RIPK1LMNAHTR1A | |
| SCHEMBL16423912 | 0.79 | RIPK1 (0.44) | RIPK1 | |
| SCHEMBL13308400 | 0.79 | HSD11B1 (0.49) | RIPK1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3466949-A1 | TRICYCLIC COMPOUND AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10112941-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3087071-B1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170327498-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-16 | — | — | US | disclosed |
| US-9751879-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-20160326173-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160318928-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-03 | — | — | US | disclosed |
| EP-3087071-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | Bristol-Myers Squibb Company (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9458156-B2 | Tricyclic compounds as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2016-06-23 | — | — | US | disclosed |
| WO-2015100282-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318928-A1 | TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, TOP2A | RIPK1 4162/4885LMNA 867/4885KDM4E 1945/4885 |
| US-20160326173-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | RIPK1 3131/4885LMNA 1318/4885KDM4E 2234/4885 |
| US-20160176864-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | RIPK1 3131/4885LMNA 1318/4885KDM4E 2234/4885 |
| US-10112941-B2 | Tricyclic compounds as anticancer agents | TP53, TK2, TOP2A | RIPK1 4060/4885LMNA 1027/4885KDM4E 2036/4885 |
| US-20170327498-A1 | NOVEL TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS | TP53, TK2, MCL1 | RIPK1 3131/4885LMNA 1318/4885KDM4E 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.